(Reuters) – Merck said on Thursday a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.
The treatment, which combines Keytruda and AstraZeneca-partnered Lynparza, failed to extend survival in patients and survival without the disease worsening in certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
The company says a full evaluation of the studies was underway.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Source link : https://www.medscape.com/s/viewarticle/merck-combination-treatment-lung-cancer-fails-late-stage-2024a100059z?src=rss
Author :
Publish date : 2024-03-21 10:55:23
Copyright for syndicated content belongs to the linked Source.